Navigation Links
A major step toward a more targeted treatment for auto-immune diseases?
Date:1/27/2008

More and more people in Western society are suffering from auto-immune diseases. Discovering the cause of these chronic inflammations is a first important step in the search for targeted medicines. VIB researchers connected to Ghent University and the Katholieke Universiteit Leuven joined forces and have elucidated the function of MALT1, a key player in controlling inflammatory reactions. They are the first to show that MALT1 is able to cleave the A20 protein, which inhibits inflammation. Scientists hope that by counteracting MALT1 they will be able to restore the bodys natural inhibition of inflammation and thus provide an alternative for treatments that tax the immune system. This would represent a profound improvement over current medicines. Their research will be published in the authoritative journal Nature Immunology.

Raging out of control?

Inflammations are our normal protective reactions against infections − they arise to help remove pathogenic organisms from our bodies. This immune response is very precise and is only possible after a complex cascade of signals. Sometimes something goes wrong in this chain of reactions, and the inflammation process becomes uncontrolled or even triggers undesired immune responses against the bodys own substances. This can lead to auto-immune diseases such as rheumatism, Crohns disease, psoriasis, and multiple sclerosis, and, in some cases, to cancer. Reining in the runaway immune system is the most obvious remedy for these kinds of diseases. But the major challenge is to do this in such a way that the immune system continues to perform its protective role. And this requires a thorough understanding of the entire process.

Proteins with a crucial function

It has long been known that the MALT1 protein plays an important role in initiating inflammation reactions. Thats why VIB researchers Beatrice Coornaert (UGent), Rudi Beyaert (UGent), Thijs Baens (K.U.Leuven) and Peter Marynen (K.U.Leuven) set out to discover exactly what its particular role is. They have now succeeded in showing that MALT1 cuts the A20 protein into pieces. They are in fact the first to find that MALT1 is a protease (a protein that cleaves other proteins) and that A20 is the protein that is cut. In normal circumstances, A20 inhibits inflammatory reactions; and, by cleaving A20, MALT1 counteracts this inhibition, allowing the inflammation to progress freely. So, both proteins play very important parts in fine-tuning the intensity of inflammatory reactions.

Prospects for new treatments

Through their research, the VIB scientists are shedding light on an important part of the process that controls our immune response. Their findings offer possibilities for the development of new medicines that counteract MALT1 and thereby restore the natural brake on the inflammation process. In this way, scientists hope to be able to provide an alternative for treatments that undermine the immune system. In addition, they hope to be able to apply this knowledge to the typical immunoreactions toward organ transplants or the treatment of cancer that is caused by genetic defects in MALT1, such as MALT lymphoma.

Joining forces

This research clearly shows the added value of combining expertise from different research groups. These important discoveries are the result of a close collaboration between researchers from the VIB Department for Molecular Biomedical Research (UGent) and the VIB Department of Molecular and Developmental Genetics.


'/>"/>

Contact: Sooike Stoops
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. ONDCP Launches First Major Initiative to Combat Teen Prescription Drug Abuse
2. Vendormate Storms into 2008 with Major Milestones for Hospital Vendor Compliance
3. Mini stress tests could help condition heart to survive major attack
4. Food and Drug Law Institute Sponsors Major Enforcement Conference
5. Delta Dental of Illinois Announces Major Gift to University of Illinois at Chicago College of Dentistry
6. ESA and EC take major step forward in GMES
7. CDI-Life Sciences Selected by CJ CheilJedang Corp. to Provide Engineering Design for Major Pharmaceutical Complex in Korea
8. Youth Impacted By Recent Mitchell Report on Major League Baseball Steroid Abuse
9. Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy
10. Venlafaxine extended-release effective for patients with major depression
11. Overwhelming Majority of Michigan Residents Favors Individual Health Insurance Market Reforms Supported by Blue Cross Blue Shield of Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... Nike ... to junior rugby in San Diego. Willis, founder of Elite Rugby Camps and current ... coaches and players every year since 2009. , “I’m excited for our eighth ...
(Date:5/4/2016)... ... 04, 2016 , ... All-Star Insurance of Northeast TX has ... of their local community. The agency pledges to select a new beneficiary every ... to bring awareness to important local causes with fundraising and other support, by ...
(Date:5/4/2016)... ... 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge , ... tooth removal, a common dental procedure, is performed for many adolescents and young adults ... in risks of complications. By providing wisdom tooth removal surgery at their office, Dr. ...
(Date:5/4/2016)... ... , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car ... procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses ... day as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 ...
(Date:5/4/2016)... TX (PRWEB) , ... May 04, 2016 , ... ... Nightstick all-LED multi-function small and compact tactical (6.7 inch) dual-light flashlights in models ... Las Vegas, model NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016  It,s time for an upgrade. There are many medical recorders on ... inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is ... world class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute lymphocytic Leukemia ...  report to their offering.       ... Global Acute Lymphocytic Leukemia Market and Competitive ... Acute Lymphocytic Leukemia pipeline products, Acute Lymphocytic ...
Breaking Medicine Technology: